<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00576784</url>
  </required_header>
  <id_info>
    <org_study_id>ATS-K-013</org_study_id>
    <secondary_id>TAK-PIO-004.2</secondary_id>
    <nct_id>NCT00576784</nct_id>
  </id_info>
  <brief_title>Metabolic Effects of Pioglitazone in Type II Diabetic Patients Previously Treated With Insulin</brief_title>
  <acronym>PIOswitch</acronym>
  <official_title>Multi Center, Open Label Study to Evaluate the Influence of Pioglitazone Treatment Over 6 Months on Metabolic Control in Type II Diabetic Patients Previously Treated With Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IKFE Institute for Clinical Research and Development</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IKFE Institute for Clinical Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the study is to demonstrate whether a switch from insulin therapy to an oral
      therapy with pioglitazone/glimepiride will lead to a deterioration of glycemic control
      (increase in HbA1c by more than 0.5 %) within a 6 month observation period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To demonstrate that reconverting type 2 diabetic patients from insulin treatment to oral
      treatment using pioglitazone in combination with or without glimepiride is possible without
      deterioration of blood glucose control.

      Primary aim is to maintain glycaemic control (HbA1c) defined as an increase in HbA1c of not
      more than 0.5 % after 6 months of treatment (visit 7) compared to baseline HbA1c value
      (screening visit V1).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients with an increase in HbA1c by 0.5 % after 6 months of treatment compared to baseline HbA1c value</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change of HbA1c Insulin resistance according to minimal model and HOMA-S analysis change of insulin resistance according to minimal model and HOMA-S analysis to baseline first phase insulin response</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pioglitazone/glimepiride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone and glimepiride</intervention_name>
    <description>switch from any insulin treatment to 30 mg pioglitazone and 3 mg glimepiride.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Actos - pioglitazone</other_name>
    <other_name>Amaryl - glimepiride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes mellitus

          -  insulin therapy &gt; 1 year

          -  residual ß-cell function (C-peptide increase in iv glucagon test)

          -  written informed consent

        Exclusion Criteria:

          -  type 1 diabetes

          -  oral therapy

          -  life-threatening disease

          -  heart failure (NYHA I-IV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IKFE</name>
      <address>
        <city>Mainz</city>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2007</study_first_submitted>
  <study_first_submitted_qc>December 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2007</study_first_posted>
  <last_update_submitted>December 17, 2007</last_update_submitted>
  <last_update_submitted_qc>December 17, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2007</last_update_posted>
  <responsible_party>
    <name_title>Prof. Thomas Forst</name_title>
    <organization>IKFE</organization>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>insulin treatment</keyword>
  <keyword>ß-cell function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

